Nicky

$RNG Stock Update

Unwarranted 20% decrease for the quarter. Despite the perceived need for RNG tech decreasing with a return to work post-COVID, earning in May were quite positive: revenue rose 32% year over year to $352 million 34% increase in subscription revenue adjusted profits of $0.27 per share were 42% higher than the $0.19 last year. beat …

$RNG Stock Update Read More »

$RNG Stock Update

RNG released an in-app calling for Salesforce. The new feature enables sales agents to make, transfer, and control phone calls directly from Salesforce, resulting in increased productivity and efficiency, and empowering sales agents to drive improved customer engagement. (With in-app calling, sales associates can easily control and manage all customer calls without ever leaving their …

$RNG Stock Update Read More »

$ETSY Stock Update

ETSY is currently has a Zacks Rank of #1 (Strong Buy). 600% over the past three years 4.4 million active sellers and nearly 82 million active buyers. $10.3 billion in gross merchandise sales, up 106.7% year over year.

$SNX Stock Update

Up 16% for the month, $36% for the quarter, and 190% for the year. Earnings Beat: EPS $1.89 beating estimates of $1.69 Revenue $4.9B beating estimates of $4.7B Announced merger with Tech Data Corporation Global investor rights law firm investigating SNX concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating …

$SNX Stock Update Read More »

$HCM Stock Update

HCM entered into a definitive agreement for the issuance of US$100 million of shares via a private placement to funds affiliated with Baring Private Equity Asia. HCM leadership expects significant growth this year as they look to accelerate oncology revenues from ELUNATE®, SULANDA® and the potential upcoming approval of savolitinib, likely to be a first-in-class …

$HCM Stock Update Read More »

$HCM Stock Update

Chinese commercial-stage biopharmaceutical company Hutchison China MediTech announced that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China for the treatment of non-pancreatic neuroendocrine tumors. Surufatinib will be marketed in China under the brand name Sulanda®. Surufatinib is Chi-Med’s first self-discovered oncology drug to be approved in China …

$HCM Stock Update Read More »

$SNX Stock Update

Business process services, data storage Spinoff Dec 1st: Concentrix Corporation (CNXC), a leading global provider of customer experience (CX) solutions and technology, announced today that it has completed its separation from SYNNEX Corporation and is now an independent, publicly traded company Earnings: $5.21 per share, beating estimate of $3.83 per share ($4.26 year over year) …

$SNX Stock Update Read More »